Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment

J Infect. 2014 Mar;68(3):252-8. doi: 10.1016/j.jinf.2013.09.033. Epub 2013 Nov 16.

Abstract

Objectives: IP-10 has been proposed as a promising alternative marker for the diagnosis of tuberculosis (TB).

Methods: In this exploratory study, we assessed the levels of serum IP-10 and TB antigen-dependent IP-10 at the time of diagnosis and after completing treatment in 32 patients with active TB.

Results: Significant changes in concentration between the time of diagnosis and the completion of therapy were observed for serum IP-10 (P < 0.001; median: 140.4 and 105.7 pg/ml, respectively) and TB antigen-dependent IP-10 (P = 0.002; median: 20,000 and 13,720 pg/ml, respectively). The proportion of TB antigen-dependent IP-10 responders did not change significantly between baseline and the completion of therapy (P = 0.35), whereas the proportion of serum IP-10 responders was significantly different (P = 0.001).

Conclusions: Serum IP-10 and TB antigen-dependent IP-10 responses to QFT-GIT antigens might be a useful biomarker for monitoring the efficacy of therapy in patients with active TB.

Keywords: IP-10; Monitoring; Tuberculosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood*
  • Chemokine CXCL10 / blood*
  • Drug Monitoring
  • Female
  • Humans
  • Interferon-gamma / blood
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Tuberculosis / blood
  • Tuberculosis / diagnosis*
  • Tuberculosis / drug therapy*
  • Tuberculosis / immunology

Substances

  • Biomarkers
  • Chemokine CXCL10
  • Interferon-gamma